Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
World J Clin Cases ; 10(1): 227-235, 2022 Jan 07.
Artículo en Inglés | MEDLINE | ID: mdl-35071521

RESUMEN

BACKGROUND: Helicobacter pylori (H. pylori) infection is a worldwide problem with increasing burden on the health sector due to its increasing rate of resistance. The conventional triple therapy (TT) is becoming obsolete with a high failure rate of eradication, necessitating the need for better alternatives or regimens. AIM: To investigate H. pylori eradication rate of TT vs modified bismuth quadruple therapy. METHODS: Ninety-two patients with dyspepsia symptoms and positive 13C-urea breath test were randomly assigned to two groups. The first group (control group) was treated for 14 d using standard TT protocol: Esomeprazole (40 mg twice daily), amoxicillin (1 g twice daily) and clarithromycin (500 mg twice daily). On the other hand, the second group was prescribed a 10-d course of modified bismuth quadruple therapy fortified with zinc carnosine: TT in addition to bismuth subcitrate (240 mg twice daily) and zinc carnosine (75 mg twice daily). A repeated 13C-urea breath test was done 4 wk after the completion of the eradication therapy. RESULTS: Among the 92 subjects, 67.4% were males and 32.6% were females. There were no differences in demographic characteristics (age, body mass index, smoking history, previous antibiotics use and ethnicity) between the modified bismuth quadruple therapy group and TT group. The eradication rate was higher [93.5% (43/46)] in the modified bismuth quadruple therapy group compared to 69.6% (32/46) in the standard TT group (P = 0.003). Of the tested predictor variables, only nationality, smoking and therapy type were statistically significant. Besides dizziness, which was recorded in modified bismuth quadruple therapy group, there were no significant differences in side effects between the two groups. CONCLUSION: Ten days of modified bismuth quadruple therapy fortified with zinc carnosine is superior to 14 d of conventional TT in eradicating H. pylori infection, with no additional significant adverse events.

3.
J Gastroenterol Hepatol ; 21(10): 1615-21, 2006 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-16928226

RESUMEN

BACKGROUND: The epidemiologic association between Helicobacter pylori and hepatitis A virus (HAV) has been evaluated by various different groups with conflicting conclusions. The aim of the present study was to determine the prevalence of HAV and H. pylori infection among adolescents attending high schools in Lebanon, and to identify the sociodemographic factors associated with their prevalence, individually and concurrently. METHODS: Nine hundred and two school students 14-18 years of age were selected randomly from 30 schools scattered all over Lebanon and tested for IgG antibodies against hepatitis A and H. pylori. Each student received a copy of a self-administered questionnaire to be completed by his/her parents inquiring about demographics, history of immunization, and prior viral hepatitis illness in the student. Bivariate analysis examined the association between different sociodemographic variables and prior HAV or H. pylori infection, and multivariate regression analysis was done to determine the factors independently associated with prior infection. RESULTS: Using ELISA the seroprevalence of antibodies against HAV was 71.3% as compared to 61.6% for anti-H. pylori. A total of 9.1% of those tested were negative for both agents. A multinomial regression analysis revealed that place of residence in relation to district or urban versus rural areas, in addition to mothers' education, were important determinants for the incidence of both agents. CONCLUSION: The low number of subjects negative for both H. pylori and HAV antibodies in Lebanon is indicative of their high prevalence in the country. It is possible that this high prevalence reflects an age-specific prevalence rather than a true association.


Asunto(s)
Anticuerpos Antibacterianos/inmunología , Anticuerpos Antivirales/inmunología , Infecciones por Helicobacter/epidemiología , Helicobacter pylori/inmunología , Virus de la Hepatitis A/inmunología , Hepatitis A/epidemiología , Adolescente , Ensayo de Inmunoadsorción Enzimática , Femenino , Infecciones por Helicobacter/complicaciones , Infecciones por Helicobacter/microbiología , Hepatitis A/complicaciones , Hepatitis A/virología , Humanos , Líbano/epidemiología , Masculino , Prevalencia , Factores de Riesgo , Encuestas y Cuestionarios
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA